WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m
Rhea-AI Summary
bioAffinity Technologies (NASDAQ: BIAF) has completed its previously announced public offering, raising $4.8 million in gross proceeds. The offering consisted of 1,921,761 shares of Common Stock (or pre-funded warrants) priced at $2.50 per share ($2.493 per pre-funded warrant).
WallachBeth Capital LLC served as the sole placement agent for the offering. The pre-funded warrants have an exercise price of $0.007 per share and will expire when exercised in full. The offering was conducted pursuant to an effective registration statement on Form S-1 filed with the SEC.
Positive
- Raised $4.8 million in gross proceeds to strengthen balance sheet
- Successful completion of public offering indicates market interest
Negative
- Potential dilution for existing shareholders
- Additional expenses for agent fees and other costs will reduce net proceeds
News Market Reaction
On the day this news was published, BIAF declined 8.92%, reflecting a notable negative market reaction. Argus tracked a peak move of +2.2% during that session. This price movement removed approximately $841K from the company's valuation, bringing the market cap to $9M at that time.
Data tracked by StockTitan Argus on the day of publication.
The offering consisted of 1,921,761 shares (the "Shares") of our Common Stock (or pre-funded warrants (the "Pre-Funded Warrants") in lieu thereof) at a purchase price of
WallachBeth Capital, LLC acted as sole placement agent for the offering.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-290480), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410,
About WallachBeth Capital LLC:
WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the closing of the offering on August 14, 2025. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-public-offering-for-4-8m-302571246.html
SOURCE WallachBeth Capital LLC
FAQ
How much did bioAffinity Technologies (BIAF) raise in their September 2025 public offering?
What was the share price for bioAffinity Technologies' (BIAF) 2025 public offering?
How many shares were offered in bioAffinity Technologies' (BIAF) September 2025 offering?
Who was the placement agent for bioAffinity Technologies' (BIAF) 2025 public offering?
What is the exercise price of the pre-funded warrants in BIAF's 2025 offering?
